NasdaqGS - Nasdaq Real Time Price USD
Metsera, Inc. (MTSR)
28.12
+1.40
+(5.24%)
At close: 4:00:01 PM EDT
28.65
+0.53
+(1.88%)
After hours: 5:27:58 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Clive A. Meanwell M.D., Ph.D. | Co-Founder & Executive Chairman | 142.91k | -- | 1958 |
| Mr. Christopher Whitten Bernard | Co-Founder, President, CEO & Director | 763.18k | -- | 1985 |
| Mr. Christopher J. Visioli | Co-Founder, CFO & Chief Business Officer | 292.31k | -- | 1977 |
| Mr. Paul L. Berns | Co-Founder & Lead Independent Director | -- | -- | 1967 |
| Dr. Brian Hubbard Ph.D. | Chief Scientific Officer | 582.97k | -- | 1973 |
| Dr. Gbolahan Amusa Benz C.F.A., M.D. | EVP of Strategic Finance & Investor Relations | 496.8k | -- | 1975 |
| Mr. Daniel Hoey | Chief Technical Operations Officer | -- | -- | 1967 |
| Mr. Matthew Lang J.D. | Chief Legal Officer & Secretary | -- | -- | 1976 |
| Ms. Nancye Green | Chief Experience Officer | -- | -- | -- |
| Mr. Michael Donovan | Chief Design Officer | -- | -- | -- |
Metsera, Inc.
3 World Trade Center
175 Greenwich Street
New York, NY 10007
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 93
Description
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Corporate Governance
Metsera, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 7, 2025 at 11:30 AM UTC
Metsera, Inc. Earnings Date
Recent Events
Related Tickers
MAZE Maze Therapeutics, Inc.
12.10
+20.88%
GPCR Structure Therapeutics Inc.
21.79
+0.14%
AARD Aardvark Therapeutics, Inc.
11.13
+6.61%
SION Sionna Therapeutics, Inc.
13.97
+2.05%
CYTK Cytokinetics, Incorporated
31.21
+0.61%
IMVT Immunovant, Inc.
15.41
+3.77%
APGE Apogee Therapeutics, Inc.
36.33
-0.85%
LXEO Lexeo Therapeutics, Inc.
2.7200
0.00%
ASND Ascendis Pharma A/S
175.69
+7.89%
SRRK Scholar Rock Holding Corporation
29.76
+2.59%